Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin

Thrombosis Research

Volumn 88, Issue 3, 1997, Pages 283-290

  Novacek, Gottfried ^a   Kapiotis, Stylianos ^a   Jilma, Bernd ^a   Quehenberger, Peter ^a   Michitsch, Albert ^a   Traindl, Otto ^b   Speiser, Wolfgang ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood coagulation; Fibrinolysis; Hemodialysis; Heparin; Prostacyclin

Indexed keywords

ANTIPLASMIN; D DIMER; DALTEPARIN; HEPARIN; PLASMIN; PROSTACYCLIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; HYPEREMIA; MALE; PRIORITY JOURNAL; TACHYCARDIA; THROMBOSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; KIDNEY FAILURE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS;

EID: 0031277784     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00255-7     Document Type: Article

References (27)

1. Keller F, Hericks K, Schuller I, Passfall J, Joerres A, Meinhold H. Thromboxane B2 blood levels and incipient system clotting in heparin free hemodialysis. ASAIO J 1995;41:173-7.
2. Lindsay RM, Prentice CRM, Davidson JF, Burton JA, McNicol GP. Hemostatic changes during dialysis associated with thrombus formation in dialysis membrane. Br Med J 1972; 4(838):454-8.
3. Tollefsen MT. Heparin: Basic and clinical pharmacology. In: Hoffmann R, Benz AJ Jr, Shattil SJ, Furie B, Cohen HJ, editors. Hematology, Basic Principles and Practice. New York-Edinburgh-London-Melbourne-Tokyo: Churchill Livingstone; 1991. p. 1436-45.
4. Swartz RD, Port FK. Preventing hemorrhage in high-risk hemodialysis. Regional versus low-dose heparin. Kidney Int 1979;16:513-8.
5. Stiekema JC Heparin and its biocompatibility. Clin Nephrol. 26(Suppl 1):1986;S3-S8.
6. Smith JA, Henderson AH, Randall MD. Endothelium-derived relaxing factor, prostanoids and endothelins. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and Thrombosis. New York-Edburgh-London-Melbourne-Tokyo: Churchill Livingstone; 1994. p. 183-97.
7. Turney JH, Fewell MR, Williams LC, Parsons V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980;2(8188):219-22.
8. Zussman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombin agent. N Engl J Med 1981;304:934-9.
9. Addonizio VP, Fisher CA, Bowen JC, Palatianos GC, Colman RW, Edmunds LH. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation. Trans Am Soc Artif Intern Organs 1981;27:304-7.
10. Smith MC, Danviriyasup K, Crow JW, Cato AE, Park GD, Hassid A, Dunn MJ. Prostacyclin substitution for heparin in longterm hemodialysis. Am J Med 1982;73:669-78.
11. Hory B, Saint-Miller Y, Perol JC. Prostacyclin as the sole antithrombotic agent for acute renal failure hemodialysis. Nephron 1983;33:71-8.
12. 2) versus heparin in hemodialysis. Trans Am Soc Artif Intern Organs 1984;30:52-4.
13. 2 prostacyclin) during high risk hemodialysis-preventing further bleeding complications. J Clin Pharmacol 1988;28:818-25.
14. Caruana RJ, Smith MC, Clyne D, Crow JW, Zinn JM, Diehl JH Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif. 9:1991;296-304.
15. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal failure and hepatic failure. Nephron 1994;66:431-7.
16. Ozasa H, Suzuki T, Ota K. Effect of oral prostacyclin on microclots in tube lines of a hemodialysis system. Nephron 1995;71:106-7.
17. Canaud B, Mion C, Arujo A, N'Guyen QV, Paleyrac G, Hemmendinger S, Cazenave JP. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron 1988;48:206-12.
18. Dibble JB, Kalra PA, Orchard MA, Turney JH, Davies JA. Prostacyclin and iloprost do not affect action of standard dose heparin on haemostatic function during haemodialysis. Thromb Res 1988;49:385-92.
19. Kuzniewski M, Sulowicz W, Hanicki Z, Kus J, Nowogrodzka-Zagorska M, Kostka-Trabka E, Bieron K, Debinska-Kiec A. Effect of heparin and prostacyclin/heparin infusion on platelet aggregation in hemodialyzed patients. Nephron 1990;56:174-8.
20. Rylance PB, Gordge MP, Ireland H, Lane DA, Weston MJ. Hemodialysis with prostacyclin (epoprostenol) alone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:281-6.
21. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-6.
22. Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of cross-linked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983;50:591-4.
23. Harpel PC Alpha2-Plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. J Clin Invest. 68:1981;46-55.
24. Saito H. The contact phase of blood coagulation. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and Thrombosis. New York-Edinburgh-London-Melbourne-Tokyo: Churchill Livingstone; 1994. p. 289-307.
25. Marcus AJ, Zucker-Franklin D. Studies on subcellular platelet particles. Blood 1964;23:389-93.
26. Gaffney PJ, Longstaff C. An overview of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and Thrombosis. New York-Edinburgh-London-Melbourne-Tokyo: Churchill Livingstone; 1994. p. 549-73.
27. Speiser W, Wojta J, Korninger C, Kirchheimer JC, Zazgornik J, Binder BR. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int 1987;32:280-3.